Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 5
2016 1
2017 2
2020 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection.
Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, Wiethoff CM, Blackbourne JL, Heinz BA, Foster D, Higgs RE, Balasubramaniam D, Wang L, Bidshahri R, Kraft L, Hwang Y, Žentelis S, Jepson KR, Goya R, Smith MA, Collins DW, Hinshaw SJ, Tycho SA, Pellacani D, Xiang P, Muthuraman K, Sobhanifar S, Piper MH, Triana FJ, Hendle J, Pustilnik A, Adams AC, Berens SJ, Baric RS, Martinez DR, Cross RW, Geisbert TW, Borisevich V, Abiona O, Belli HM, de Vries M, Mohamed A, Dittmann M, Samanovic M, Mulligan MJ, Goldsmith JA, Hsieh CL, Johnson NV, Wrapp D, McLellan JS, Barnhart BC, Graham BS, Mascola JR, Hansen CL, Falconer E. Jones BE, et al. Among authors: blackbourne jl. bioRxiv. 2020 Oct 1:2020.09.30.318972. doi: 10.1101/2020.09.30.318972. Preprint. bioRxiv. 2020. PMID: 33024963 Free PMC article. Updated.
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.
Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, Wiethoff CM, Blackbourne JL, Heinz BA, Foster D, Higgs RE, Balasubramaniam D, Wang L, Zhang Y, Yang ES, Bidshahri R, Kraft L, Hwang Y, Žentelis S, Jepson KR, Goya R, Smith MA, Collins DW, Hinshaw SJ, Tycho SA, Pellacani D, Xiang P, Muthuraman K, Sobhanifar S, Piper MH, Triana FJ, Hendle J, Pustilnik A, Adams AC, Berens SJ, Baric RS, Martinez DR, Cross RW, Geisbert TW, Borisevich V, Abiona O, Belli HM, de Vries M, Mohamed A, Dittmann M, Samanovic MI, Mulligan MJ, Goldsmith JA, Hsieh CL, Johnson NV, Wrapp D, McLellan JS, Barnhart BC, Graham BS, Mascola JR, Hansen CL, Falconer E. Jones BE, et al. Among authors: blackbourne jl. Sci Transl Med. 2021 May 12;13(593):eabf1906. doi: 10.1126/scitranslmed.abf1906. Epub 2021 Apr 5. Sci Transl Med. 2021. PMID: 33820835 Free PMC article.
Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR®/ABASAGLAR®) approved in the European Union.
Byrd RA, Owens RA, Blackbourne JL, Coutant DE, Farmen MW, Michael MD, Moyers JS, Schultze AE, Sievert MK, Tripathi NK, Vahle JL. Byrd RA, et al. Among authors: blackbourne jl. Regul Toxicol Pharmacol. 2017 Aug;88:56-65. doi: 10.1016/j.yrtph.2017.05.013. Epub 2017 May 17. Regul Toxicol Pharmacol. 2017. PMID: 28526658
An Investigative Study of Pancreatic Exocrine Biomarkers, Histology, and Histomorphometry in Male Zucker Diabetic Fatty (ZDF) Rats Given Dulaglutide by Subcutaneous Injection Twice Weekly for 13 Weeks.
Usborne A, Byrd RA, Meehan J, Blackbourne JL, Sullivan J, Poitout-Belissent F, Prefontaine A, Martin JA, Vahle JL. Usborne A, et al. Among authors: blackbourne jl. Toxicol Pathol. 2015 Dec;43(8):1093-102. doi: 10.1177/0192623315596857. Epub 2015 Aug 12. Toxicol Pathol. 2015. PMID: 26269615 Clinical Trial.
Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey (Macaca fasicularis): A summary of three pre-clinical immunotoxicology evaluations.
Komocsar WJ, Blackbourne JL, Halstead CA, Winstead CJ, Wierda D. Komocsar WJ, et al. Among authors: blackbourne jl. J Immunotoxicol. 2016;13(1):7-19. doi: 10.3109/1547691X.2014.994793. Epub 2015 Sep 4. J Immunotoxicol. 2016. PMID: 25585959